A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
| Autor: | Roy, A.C., Park, S.R., Cunningham, D. *, Kang, Y.K., Chao, Y., Chen, L.T., Rees, C., Lim, H.Y., Tabernero, J., Ramos, F.J., Kujundzic, M., Cardic, M.B., Yeh, C.G., de Gramont, A. |
|---|---|
| Zdroj: | In Annals of Oncology June 2013 24(6):1567-1573 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|